source
- BridgeBio's heart drug Attruby exceeds sales expectations, shifting investor outlookBridgeBio prepared to sell its heart drug Attruby on its own, prompting skepticism from investors and analysts who doubted the company could compete with larger rivals. The drug far outperformed f…
- Coultreon secures $125M Series A to advance oral immune drug into Phase 2 trialsCoultreon Biopharma announced a $125 million Series A financing round to fund development of an oral drug it licensed from Galapagos. The round was led by Sofinnova Investments and included nine i…